{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:03:52Z","timestamp":1784174632706,"version":"3.55.0"},"reference-count":45,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"unspecified","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Ruhr University of Bochum Innovation Fund","award":["IF-028-22"],"award-info":[{"award-number":["IF-028-22"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,6,18]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Psoriatic arthritis is a chronic inflammatory disease that can affect the axial skeleton as well as the joints and enthesis. Following the failure of conventional synthetic disease-modifying antirheumatic drugs (DMARDs), numerous biological DMARDs (b-DMARDs) or targeted synthetic DMARDs are now available, although current guidelines do not recommend a specific mode of action in the absence of comorbidities or contraindications. The aim of the study is to identify markers associated with the achievement of Minimal Disease Activity (MDA) at week 16 in patients treated with tumour necrosis factor inhibitors (TNFi), interleukin-17 inhibitors (IL-17i) or interleukin-23 inhibitors (IL-23i).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A total of 100 patients with active psoriatic arthritis (PsA) with a clinical indication for treatment escalation of methotrexate (MTX) (ie, non-response or intolerance to MTX) to a b-DMARD are to be included in the prospective observational cohort study. Patients are escalated according to physician\u2019s choice to one of the following modes of action: TNFi, IL-23i or IL-17i. Participant recruitment is currently ongoing and is expected to be completed in July 2026. This protocol was finalised prior to database lock and before any outcome analyses were conducted. The primary endpoint is achieving MDA at 16 weeks. Secondary endpoints include changes in clinical scores: Psoriasis Area and Severity Index 75% improvement, Disease Activity in Psoriatic Arthritis, Nail Psoriasis Severity Index and biomarker evaluation from blood and skin biopsy samples. Machine learning techniques will be applied to identify marker patterns associated with treatment response, while treatment-specific marker interactions will be explored on a hypothesis-generating basis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval was obtained from the Ruhr University Bochum Ethics Committee (no. 23-7918) on 1 December 2024 for study protocol number 2.0 (30 October 2024). Study results will be published in an international journal, regardless of whether the results are positive or negative. Results will be communicated to the scientific community and healthcare professionals at the conference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>DRKS00032573.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-115708","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:20:25Z","timestamp":1784172025000},"page":"e115708","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a predictive marker panel for the individualised bDMARD therapy of psoriatic arthritis: protocol for a prospective observational study (Integrate-PsA)"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3929-2797","authenticated-orcid":false,"given":"Prem Kant","family":"Shekhar","sequence":"first","affiliation":[{"name":"Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5600-8560","authenticated-orcid":false,"given":"Anna","family":"Mai","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Melides","sequence":"additional","affiliation":[{"name":"Rheumatology Center Ruhr Area, University Hospital of the Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2361-2785","authenticated-orcid":false,"given":"Christian","family":"Sch\u00fctz","sequence":"additional","affiliation":[{"name":"Rheumatology Center Ruhr Area, University Hospital of the Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1056-1636","authenticated-orcid":false,"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Rheumatology Center Ruhr Area, University Hospital of the Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5360-0419","authenticated-orcid":false,"given":"Ingo","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Department of Molecular Immunology, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4093-1200","authenticated-orcid":false,"given":"Nikolaos","family":"Stavropoulos","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of the Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk G.","family":"Bechara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, ICH - International Center for Hidradenitis suppurativa \/ Acne inversa, Ruhr-University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eggert","family":"Stockfleth","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of the Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5175-4326","authenticated-orcid":false,"given":"Nina","family":"Timmesfeld","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[{"name":"Rheumatology Center Ruhr Area, University Hospital of the Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-6207","authenticated-orcid":false,"given":"Philipp","family":"Sewerin","sequence":"additional","affiliation":[{"name":"Rheumatology Center Ruhr Area, University Hospital of the Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2026071520201257000_16.7.e115708.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06435.x"},{"key":"2026071520201257000_16.7.e115708.2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"2026071520201257000_16.7.e115708.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03463.x"},{"key":"2026071520201257000_16.7.e115708.4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s00393-016-0094-2","article-title":"Wie h\u00e4ufig sind muskuloskeletale Erkrankungen in Deutschland?","volume":"75","author":"Zink","year":"2016","journal-title":"Z Rheumatol"},{"key":"2026071520201257000_16.7.e115708.5","first-page":"1354","article-title":"Incidence and prevalence of psoriatic arthritis: a systematic review","volume":"35","author":"Alamanos","year":"2008","journal-title":"J Rheumatol"},{"key":"2026071520201257000_16.7.e115708.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.001"},{"key":"2026071520201257000_16.7.e115708.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100034"},{"key":"2026071520201257000_16.7.e115708.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123582","article-title":"A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis","volume":"10","author":"Michelsen","year":"2015","journal-title":"PLoS One"},{"key":"2026071520201257000_16.7.e115708.9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00296-017-3809-z","article-title":"Secular trends in sickness absence among Swedish patients with ankylosing spondylitis and psoriatic arthritis","volume":"38","author":"Nielsen","year":"2018","journal-title":"Rheumatol Int"},{"key":"2026071520201257000_16.7.e115708.10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu264"},{"key":"2026071520201257000_16.7.e115708.11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/acr.22576","article-title":"Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study","volume":"68","author":"Kavanaugh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026071520201257000_16.7.e115708.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"2026071520201257000_16.7.e115708.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2026071520201257000_16.7.e115708.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2026071520201257000_16.7.e115708.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2026071520201257000_16.7.e115708.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217163"},{"key":"2026071520201257000_16.7.e115708.17","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000880","article-title":"Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry","volume":"5","author":"Mease","year":"2019","journal-title":"RMD Open"},{"key":"2026071520201257000_16.7.e115708.18","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.38995","article-title":"Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis","volume":"67","author":"Belasco","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026071520201257000_16.7.e115708.19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.semarthrit.2019.06.001","article-title":"Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis","volume":"49","author":"Lu","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2026071520201257000_16.7.e115708.20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001117","article-title":"Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis","volume":"6","author":"Ruyssen-Witrand","year":"2020","journal-title":"RMD Open"},{"key":"2026071520201257000_16.7.e115708.21","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211014010","article-title":"Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review","volume":"13","author":"Magee","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026071520201257000_16.7.e115708.22","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-018-0781-x","article-title":"Novel Concepts in Psoriatic Arthritis Management: Can We Treat to Target?","volume":"20","author":"Tucker","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"2026071520201257000_16.7.e115708.23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-021-02715-4","article-title":"The difference of lipid profiles between psoriasis with arthritis and psoriasis without arthritis and sex-specific downregulation of methotrexate on the apolipoprotein B\/apolipoprotein A-1 ratio","volume":"24","author":"Wang","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2026071520201257000_16.7.e115708.24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13075-017-1417-7","article-title":"Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study","volume":"19","author":"Jadon","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2026071520201257000_16.7.e115708.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.24172"},{"key":"2026071520201257000_16.7.e115708.26","doi-asserted-by":"crossref","unstructured":"Hermansson E , Svensson D . On discovering treatment-effect modifiers using virtual twins and causal forest ML in the presence of prognostic biomarkers. 2021:624\u201340.","DOI":"10.1007\/978-3-030-86973-1_44"},{"key":"2026071520201257000_16.7.e115708.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049822","article-title":"IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)","volume":"11","author":"Eyerich","year":"2021","journal-title":"BMJ Open"},{"key":"2026071520201257000_16.7.e115708.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122259"},{"key":"2026071520201257000_16.7.e115708.29","first-page":"1302","article-title":"Measuring dactylitis in clinical trials: which is the best instrument to use?","volume":"34","author":"Healy","year":"2007","journal-title":"J Rheumatol"},{"key":"2026071520201257000_16.7.e115708.30","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/ijd.ijd_420_23","article-title":"Disease Assessment in Psoriasis","volume":"68","author":"Manchanda","year":"2023","journal-title":"Indian J Dermatol"},{"key":"2026071520201257000_16.7.e115708.31","first-page":"S64","article-title":"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI)","volume":"63 Suppl 11","author":"Mease","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026071520201257000_16.7.e115708.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.22469"},{"key":"2026071520201257000_16.7.e115708.33","first-page":"S47","article-title":"Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S)","volume":"63 Suppl 11","author":"Zochling","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026071520201257000_16.7.e115708.34","doi-asserted-by":"publisher","DOI":"10.1002\/art.20549"},{"key":"2026071520201257000_16.7.e115708.35","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-1227"},{"key":"2026071520201257000_16.7.e115708.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2026071520201257000_16.7.e115708.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"2026071520201257000_16.7.e115708.38","unstructured":"Zeng Z , Lu Y , Shen J , et al . A Random Interaction Forest for Prioritizing Predictive Biomarkers. arXiv 2019. doi:10.48550\/arXiv.1910.01786"},{"key":"2026071520201257000_16.7.e115708.39","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1093\/bioinformatics\/btac405","article-title":"Identifying interactions in omics data for clinical biomarker discovery using symbolic regression","volume":"38","author":"Christensen","year":"2022","journal-title":"Bioinformatics"},{"key":"2026071520201257000_16.7.e115708.40","doi-asserted-by":"crossref","DOI":"10.1186\/s12859-023-05143-0","article-title":"Identification of prognostic and predictive biomarkers in high-dimensional data with PPLasso","volume":"24","author":"Zhu","year":"2023","journal-title":"BMC Bioinformatics"},{"key":"2026071520201257000_16.7.e115708.41","unstructured":"Lundberg SM , Erion GG , Lee S-I . Consistent Individualized Feature Attribution for Tree Ensembles. arXiv 2018. doi:10.48550\/arXiv.1802.03888"},{"key":"2026071520201257000_16.7.e115708.42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s42256-019-0138-9","article-title":"From Local Explanations to Global Understanding with Explainable AI for Trees","volume":"2","author":"Lundberg","year":"2020","journal-title":"Nat Mach Intell"},{"key":"2026071520201257000_16.7.e115708.43","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13075-022-02838-2","article-title":"Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning","volume":"24","author":"Queiro","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2026071520201257000_16.7.e115708.44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13075-024-03277-x","article-title":"Prediction of ineffectiveness of biological drugs using machine learning and explainable AI methods: data from the Austrian Biological Registry BioReg","volume":"26","author":"Ukalovic","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"2026071520201257000_16.7.e115708.45","doi-asserted-by":"crossref","unstructured":"Friedman JH , Popescu BE . Predictive learning via rule ensembles. Ann Appl Stat 2008;2. doi:10.1214\/07-AOAS148","DOI":"10.1214\/07-AOAS148"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-115708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T03:20:35Z","timestamp":1784172035000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-115708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,15]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjopen-2025-115708"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-115708","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}